Insights

Making sense of chaos in the GLP-1 space

Melanotan II is sold as a tanning shortcut. See the FDA's own safety language, the published case reports, and where the 2026 peptide review stands.

Patient shares her real Trinity Meds experience: fast approval to pricing to the rating discrepancy. See tradeoffs and what to know before ordering.

Do GLP-1s reduce drinking? A 2026 trial says yes for people with obesity, but two trials missed their goal. What the evidence really shows.

Told to stop your GLP-1 before surgery, or to continue? Five guidance documents disagree. See what each says and what to ask your team.

The FTC sued Hims & Hers over subscription billing and health data. See what it alleges, the company's response, and what to check on your account.

GLP-1s are now 96% of obesity treatment for ages 13 to 25. See which are approved for teens, which are not, and what to ask a pediatrician.

She paid $149 for her first month of compounded tirzepatide at AltRx and had it in 3 days. No labs, no ID check. See the pros, tradeoffs, and costs.

Federal guidance now recommends 1.2 to 1.6 g of protein per kg daily. See what that means in grams and why it matters on a GLP-1.

2027 marketplace enrollment runs November 1 to January 15. December 15 is the cutoff for coverage that starts January 1.

The FDA proposed limiting large-scale compounded GLP-1s. See what is actually being decided and which pathway stays open.

A rejected Medicare GLP-1 Bridge claim is usually a paperwork step, not a denial. See the four reasons and what to ask your pharmacy.

A real patient walks through GobyMeds: $299/month compounded tirzepatide, $274 with our code, no video call, and 8 days from payment to doorstep.